Actinium Pharmaceuticals (ATNM) Assets Average (2011 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Assets Average of $48.6 million for Q1 2026, down 33.21% year-over-year from $72.8 million in Q1 2025, and down 9.93% quarter-over-quarter from $54.0 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Assets Average (2011 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Assets Average for 16 consecutive years, with $48.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 33.21% year-over-year to $48.6 million; the TTM figure through Mar 2026 stood at $48.6 million (down 33.21% YoY), while the FY2025 annual figure was $64.3 million, down 18.74% from the prior year.
- Assets Average eased to $48.6 million in Q1 2026 per ATNM's latest filing, from $54.0 million in the prior quarter.
- Across five years, Assets Average topped out at $119.3 million in Q3 2022 and bottomed at $48.6 million in Q1 2026.
- Historically, Assets Average has averaged $84.6 million across 5 years, with a median of $85.2 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average jumped 41.25% — and 2026, when it tumbled 33.21%.
- Actinium Pharmaceuticals' Assets Average stood at $115.5 million in 2022, then declined by 26.24% to $85.2 million in 2023, then slipped by 6.68% to $79.5 million in 2024, then sank by 32.13% to $54.0 million in 2025, then dropped by 9.93% to $48.6 million in 2026.
- Business Quant data shows ATNM's Assets Average at $48.6 million in Q1 2026, $54.0 million in Q4 2025, and $59.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 19.82 Bn |
| 10 | Actinium Pharmaceuticals | 35.17 Mn | 35.17 Mn | - | 42.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.80 Mn |
| Mar 31, 2026 | 48.61 Mn |
| Dec 31, 2025 | 53.96 Mn |
| Sep 30, 2025 | 59.58 Mn |
| Jun 30, 2025 | 65.83 Mn |
| Mar 31, 2025 | 72.77 Mn |
| Dec 31, 2024 | 79.51 Mn |
| Sep 30, 2024 | 85.99 Mn |
| Jun 30, 2024 | 89.11 Mn |
| Mar 31, 2024 | 84.90 Mn |
| Dec 31, 2023 | 85.19 Mn |
| Sep 30, 2023 | 94.00 Mn |
| Jun 30, 2023 | 100.54 Mn |
| Mar 31, 2023 | 108.11 Mn |
| Dec 31, 2022 | 115.50 Mn |
| Sep 30, 2022 | 119.31 Mn |
| Jun 30, 2022 | 98.18 Mn |
| Mar 31, 2022 | 77.48 Mn |
| Dec 31, 2021 | 82.43 Mn |
| Sep 30, 2021 | 84.47 Mn |